This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.
BEAt-DKD is funded under the "Health" priority, which is an investment in our health and, on a larger scale, an investment in a healthy workforce, a healthy economy and lower public health bills.
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
The EFPIA Manager Research Partnerships plays a critical role in enabling participation of EFPIA members in collaborative research and development in the framework of private-private and public-private partnerships, such as but not limited to the Innovative Medicines Initiative or EU framework programmes.